PMID- 30193527 OWN - NLM STAT- MEDLINE DCOM- 20190509 LR - 20190509 IS - 0042-773X (Print) IS - 0042-773X (Linking) VI - 64 IP - 5 DP - 2018 Summer TI - Antithrombotics today. PG - 565-574 AB - Over the last 10 years some new drugs affecting blood clotting - antithrombotics - were invented. For more than half a century only warfarin and heparin were available. A better understanding of the pathways involved in activation of blood clotting, the links between these systems, and the impact of thrombosis on inflammation, have led to identification of new targets and development of new drugs, especially new antiplatelet drugs and anticoagulants. With the advent of new drugs into clinical practice, treatment options of thrombotic complications are expanding. However, it is always necessary to get familiar with the drug and its properties and to know its limitations. This is the only way to offer patients the best practices. Key words: anticoagulant - antithrombotic - Direct Oral AntiCoagulant (DOAC) - laboratory monitoring - Low-Molecu-lar-Weight Heparins (LMWH) - New Oral Anticoagulants/Non-vitamin K Oral AntiCoagulants (NOAC) - unfractionated heparin (UFH) - warfarin. FAU - Matyskova, Miloslava AU - Matyskova M FAU - Michalcova, Jana AU - Michalcova J FAU - Penka, Miroslav AU - Penka M LA - eng PT - Journal Article TT - Antitrombotika dnes. PL - Czech Republic TA - Vnitr Lek JT - Vnitrni lekarstvi JID - 0413602 RN - 0 (Anticoagulants) RN - 0 (Fibrinolytic Agents) RN - 0 (Heparin, Low-Molecular-Weight) RN - 5Q7ZVV76EI (Warfarin) RN - 9005-49-6 (Heparin) SB - IM MH - *Anticoagulants/therapeutic use MH - Fibrinolytic Agents/therapeutic use MH - Heparin/therapeutic use MH - Heparin, Low-Molecular-Weight/therapeutic use MH - Humans MH - Warfarin/therapeutic use EDAT- 2018/09/09 06:00 MHDA- 2019/05/10 06:00 CRDT- 2018/09/09 06:00 PHST- 2018/09/09 06:00 [entrez] PHST- 2018/09/09 06:00 [pubmed] PHST- 2019/05/10 06:00 [medline] AID - 105477 [pii] PST - ppublish SO - Vnitr Lek. 2018 Summer;64(5):565-574.